Logo

Cenix BioScience Providing RNAi Services to Schering

Feb 28, 2005

NEW YORK, Feb. 28 (GenomeWeb News) - Cenix BioScience of Dresden, Germany is providing Schering with RNA interference research services to prioritize drug targets, Cenix said today.

 

Under two projects, which began at the end of 2004, Cenix has been validating candidate genes for drug targets provided by Schering using high-throughput RNAi and high-content phenotype analyses in human and mouse cell lines.

 

The companies disclosed neither the disease areas nor financial terms of the agreement.

Breaking News
The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.